Shin Nippon Biomedical Laboratories, Ltd. (FRA:YB3)
Germany flag Germany · Delayed Price · Currency is EUR
10.10
+0.25 (2.54%)
Last updated: Dec 4, 2025, 8:02 AM CET

FRA:YB3 Ratios and Metrics

Millions EUR. Fiscal year is Apr - Mar.
Fiscal Year
CurrentFY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2016 - 2020
Period Ending
Dec '25 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 2016 - 2020
Market Capitalization
417368387793523224
Upgrade
Market Cap Growth
10.25%-4.96%-51.14%51.44%133.49%20.59%
Upgrade
Enterprise Value
566517472848550283
Upgrade
Last Close Price
10.008.808.6716.9910.964.64
Upgrade
PE Ratio
15.5812.1011.4318.899.917.95
Upgrade
PS Ratio
2.091.842.394.563.981.93
Upgrade
PB Ratio
1.901.491.854.343.581.84
Upgrade
P/TBV Ratio
2.021.571.984.673.651.88
Upgrade
P/FCF Ratio
33.28---16.017.91
Upgrade
P/OCF Ratio
8.418.4730.0128.5911.866.13
Upgrade
EV/Sales Ratio
2.952.582.914.884.182.44
Upgrade
EV/EBITDA Ratio
11.4014.9612.7617.8913.819.90
Upgrade
EV/EBIT Ratio
17.2228.0418.4923.3517.6814.55
Upgrade
EV/FCF Ratio
45.15---16.8210.00
Upgrade
Debt / Equity Ratio
1.000.860.770.710.460.80
Upgrade
Debt / EBITDA Ratio
6.376.164.342.741.703.41
Upgrade
Debt / FCF Ratio
17.50---2.073.45
Upgrade
Asset Turnover
0.390.380.400.520.470.40
Upgrade
Inventory Turnover
1.301.241.242.061.911.87
Upgrade
Quick Ratio
0.610.630.690.730.790.86
Upgrade
Current Ratio
1.101.131.311.141.211.24
Upgrade
Return on Equity (ROE)
12.29%13.10%18.24%26.26%40.30%22.82%
Upgrade
Return on Assets (ROA)
2.05%2.21%3.90%6.79%6.88%4.16%
Upgrade
Return on Capital (ROIC)
2.50%2.77%4.93%8.86%9.14%5.28%
Upgrade
Return on Capital Employed (ROCE)
4.70%4.70%7.90%14.50%16.20%10.10%
Upgrade
Earnings Yield
6.42%8.27%8.75%5.29%10.09%12.58%
Upgrade
FCF Yield
3.00%-6.41%-10.25%-0.73%6.25%12.64%
Upgrade
Dividend Yield
2.96%3.51%3.53%2.04%2.03%1.66%
Upgrade
Payout Ratio
46.37%42.65%37.48%41.01%11.60%5.65%
Upgrade
Buyback Yield / Dilution
---0.00%--
Upgrade
Total Shareholder Return
3.03%3.51%3.53%2.04%2.03%1.66%
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.